A share price of PTC Therapeutics Inc [PTCT] is currently trading at $45.27, up 4.55%. An important factor to consider is whether the stock is rising or falling in short-term value. The PTCT shares have lost -11.43% over the last week, with a monthly amount drifted -8.47%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
PTC Therapeutics Inc [NASDAQ: PTCT] stock has seen the most recent analyst activity on June 17, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $80. Previously, BofA Securities upgraded its rating to Buy on May 09, 2025, and kept the price target unchanged to $68. On May 07, 2025, upgrade upgraded it’s rating to Neutral but maintained its price target of $40 on the stock. BofA Securities upgraded its rating to a Neutral and increased its price target to $55 on March 11, 2025. Scotiabank initiated its recommendation with a Sector Perform and recommended $55 as its price target on March 07, 2025. Morgan Stanley upgraded its rating to Overweight for this stock on December 13, 2024, and upped its price target to $67. In a note dated December 03, 2024, RBC Capital Mkts upgraded an Outperform rating on this stock and boosted its target price from $39 to $63.
PTC Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $30.08 and $58.38. Currently, Wall Street analysts expect the stock to reach $70 within the next 12 months. PTC Therapeutics Inc [NASDAQ: PTCT] shares were valued at $45.27 at the most recent close of the market. An investor can expect a potential return of 54.63% based on the average PTCT price forecast.
Analyzing the PTCT fundamentals
Trailing Twelve Months sales for PTC Therapeutics Inc [NASDAQ:PTCT] were 1.76B which represents -4.19% decline. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at 0.41%, Pretax Profit Margin comes in at 0.38%, and Net Profit Margin reading is 0.36%. To continue investigating profitability, this company’s Return on Assets is posted at 0.24, Equity is -0.99 and Total Capital is 0.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-1.88.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.73 points at the first support level, and at 42.19 for the second support level. However, for the 1st resistance point, the stock is sitting at 46.40, and for the 2nd resistance point, it is at 47.53.
Ratios To Look Out For
To put it in perspective, the Current Ratio for PTC Therapeutics Inc [NASDAQ:PTCT] is 3.62. On the other hand, the Quick Ratio is 3.57, and the Cash Ratio is 1.62. Considering the valuation of this stock, the price to sales ratio is 2.04 and price to earnings (TTM) ratio is 6.49.
Transactions by insiders
Recent insider trading involved Klein Matthew B., CHIEF EXECUTIVE OFFICER, that happened on Aug 05 ’25 when 10739.0 shares were sold. Officer, Klein Matthew B. completed a deal on Aug 05 ’25 to buy 10739.0 shares. Meanwhile, CHIEF FINANCIAL OFFICER Gravier Pierre sold 2516.0 shares on Jul 15 ’25.
